Climb Bio Director Departs, Board Changes Announced

Ticker: CLYM · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1768446

Sentiment: neutral

Topics: management-change, board-composition, officer-compensation

TL;DR

Climb Bio director Rickman out, new board members in. Watch for comp changes.

AI Summary

Climb Bio, Inc. announced on June 12, 2025, the departure of Director Dr. David S. Rickman. The company also reported on the election of new directors and changes in compensatory arrangements for certain officers. This filing follows a period of significant corporate activity for the pharmaceutical preparations company.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Director departures and changes in compensatory arrangements can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Numbers

Key Players & Entities

FAQ

Who is the departing director and when did their departure become effective?

Dr. David S. Rickman is the departing director, and the event was reported as of June 12, 2025.

What other key items are covered in this 8-K filing besides director departure?

The filing also covers the election of directors and changes to compensatory arrangements of certain officers.

What is Climb Bio, Inc.'s former company name?

Climb Bio, Inc.'s former company name was Eliem Therapeutics, Inc.

What is the SEC file number for Climb Bio, Inc.?

The SEC file number for Climb Bio, Inc. is 001-40708.

Where is Climb Bio, Inc. headquartered?

Climb Bio, Inc. is headquartered at 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 by Dr. David S. Rickman regarding Climb Bio, Inc. (CLYM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing